News & Events
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Crinetics Pharmaceuticals reported second quarter 2024 financial and provided a business update on clinical progress.
READ MORECrinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
Crinetics launches ACRO/TRUTH, a website and educational initiative aimed at highlighting the various acromegaly treatment challenges.
READ MORECrinetics Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its common stock to eighteen new non-executive employees.
READ MOREEY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
Ernst & Young LLP announces that Scott Struthers, Ph. D. , founder and chief executive officer of Crinetics, was named an Entrepreneur Of The Year® 2024 Pacific Southwest Award winner.
READ MORECrinetics Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 158,000 shares of its common stock to nine new non-executive employees.
READ MORECrinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
Crinetics announced initial findings from the development program of its second clinical product candidate, atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist.
READ MORECrinetics Presents New Data at ENDO 2024 that Increases that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
Crinetics Pharmaceuticals presents new data from its clinical development program evaluating oral, once-daily investigational paltusotine in acromegaly.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
